<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: Epithelial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> can be initiated by activating mutations in components of the <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase signaling pathway such as v-raf murine <z:hpo ids='HP_0100242'>sarcoma</z:hpo> <z:mp ids='MP_0001799'>viral</z:mp> oncogene homolog B1 (BRAF), v-Ki-ras2 Kirsten rat <z:hpo ids='HP_0100242'>sarcoma</z:hpo> <z:mp ids='MP_0001799'>viral</z:mp> oncogene homolog (KRAS), or epidermal growth factor receptor (EGFR) </plain></SENT>
<SENT sid="1" pm="."><plain>Human intestinal serrated <z:mpath ids='MPATH_491'>polyps</z:mpath> are a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of benign lesions, but some progress to <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumors</z:e> that arise from these <z:mpath ids='MPATH_491'>polyps</z:mpath> frequently contain activating mutations in BRAF or KRAS, but little is known about the role of EGFR activation in their development </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: <z:mpath ids='MPATH_491'>Polyp</z:mpath> samples were obtained from adults during screening colonoscopies at Mount Sinai Hospital in New York </plain></SENT>
<SENT sid="4" pm="."><plain>We measured levels of EGFR protein and phosphorylation in human serrated <z:mpath ids='MPATH_491'>polyps</z:mpath> by immunohistochemical and immunoblot analyses </plain></SENT>
<SENT sid="5" pm="."><plain>We generated transgenic mice that express the ligand for EGFR, <z:chebi fb="5" ids="28304">Heparin</z:chebi>-binding EGF-like growth factor (HB-EGF), in the intestine </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: EGFR and the extracellular-regulated kinases (ERK)1/2 were phosphorylated in serrated areas of human <z:mpath ids='MPATH_140'>hyperplastic polyps</z:mpath> (HPPs), sessile serrated <z:mpath ids='MPATH_270'>adenomas</z:mpath>, and traditional serrated <z:mpath ids='MPATH_270'>adenomas</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>EGFR and ERK1/2 were phosphorylated in the absence of KRAS or BRAF activating mutations in a subset of HPP </plain></SENT>
<SENT sid="8" pm="."><plain>Transgenic expression of the EGFR ligand HB-EGF in the intestines of mice promoted development of small cecal serrated <z:mpath ids='MPATH_491'>polyps</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>Mice that expressed a combination of HB-EGF and US28 (a constitutively active, G-protein-coupled receptor that increases processing of HB-EGF from the membrane) rapidly developed large cecal serrated <z:mpath ids='MPATH_491'>polyps</z:mpath> </plain></SENT>
<SENT sid="10" pm="."><plain>These <z:mpath ids='MPATH_491'>polyps</z:mpath> were similar to HPPs and had increased phosphorylation of EGFR and ERK1/2 within the serrated epithelium </plain></SENT>
<SENT sid="11" pm="."><plain>Administration of pharmacologic inhibitors of EGFR or MAPK to these transgenic mice significantly reduced <z:mpath ids='MPATH_491'>polyp</z:mpath> development </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Activation of EGFR signaling in the intestine of mice promotes development of serrated <z:mpath ids='MPATH_491'>polyps</z:mpath> </plain></SENT>
<SENT sid="13" pm="."><plain>EGFR signaling also is activated in human HPPs, sessile serrated <z:mpath ids='MPATH_270'>adenomas</z:mpath>, and traditional serrated <z:mpath ids='MPATH_270'>adenomas</z:mpath> </plain></SENT>
</text></document>